All the Active Ingredient Drugs
Tyrosine Kinase Inhibitor. cabozantinib 20/40/60 mg. FC tabs:30 X20/40/60 mg
As monother.
For RCC, HCC DTC and NET, recommen. dose is 60 mg/d. Continue until ptt is no longer clinically benefiting from ther. or until unacceptable tox. occurs.
In combin. with nivolumab in first-line advan. RCC
40 mg/d in combin. with nivolumab. See full prescript. info.
Renal cell carcinoma (RCC)
as monother. for advan. RCC:
- as first-line tmt of adlts with intermediate or poor risk, per IMDC criteria.
- in adlts following prior vasc. endothelial growth factor (VEGF)-targeted ther.
in combin. with nivolumab, for the first-line tmt of adv. RCC in adlts
Hepatocellular carcinoma (HCC)
as monother. for hepatocellular carcinoma (HCC), in adlts with Child-Pugh Class A hepatic impairm. who have previously been treated with sorafenib.
Differentiated thyroid carcinoma (DTC)
as monother. for adlts with locally adv. or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior system. ther.
Neuroendocrine Tumours (NET)
For adlts with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior syst. ther. other than somatostatin analogues.
C/I: Hypersens.
